# Corrigenda and Addenda

# Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon $\beta$ -1b: Observational Study

Volker Limmroth<sup>1</sup>, MD; Kirsten Bayer-Gersmann<sup>2</sup>, BEng; Christian Mueller<sup>3</sup>, PhD; Markus Schürks<sup>3</sup>, MSc, MD

## **Corresponding Author:**

Markus Schürks, MSc, MD Bayer Vital GmbH Medical Affairs, Neurology, Immunology & Ophthalmology Leverkusen, 51368 Germany

Phone: 49 214 30 51455

Email: markus.schuerks@bayer.com

### **Related Article:**

Correction of: <a href="https://formative.jmir.org/2022/3/e31972">https://formative.jmir.org/2022/3/e31972</a>
(JMIR Form Res 2022;6(3):e38002) doi: <a href="https://formative.jmir.org/2022/3/e31972">10.2196/38002</a>

In "Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon  $\beta$ -1b: Observational Study" (JMIR Form Res 2022;6(3):e31972) the authors noted one error.

In the originally published article, Figure 2 appeared incorrectly (as shown in the Multimedia Appendix 1).

The correct Figure 2 is provided below.

The correction will appear in the online version of the paper on the JMIR Publications website on March 17, 2022, together with the publication of this correction notice. Because this was made after submission to PubMed, PubMed Central, and other full-text repositories, the corrected article has also been resubmitted to those repositories.




<sup>&</sup>lt;sup>1</sup>Clinic for Neurology and Palliative Medicine, Municipal Hospital Köln-Merheim, Cologne, Germany

<sup>&</sup>lt;sup>2</sup>Institut Dr. Schauerte, Munich, Germany

<sup>&</sup>lt;sup>3</sup>Bayer Vital GmbH, Leverkusen, Germany

Figure 2. (A) Compliance overall and by gender and age group, (B) patients categorized by percentage of interferon  $\beta$ -1b injections missed (based on an expected frequency of 1 injection every other day), and (C) adherence overall and by gender and age group, analyzed (i) prospectively and (ii) retrospectively. Compliance at 6 and 12 months was assessed in patients with  $\geq$ 6 and  $\geq$ 12 months of injection-related data, respectively. In the box and whisker plots, the colored bars indicate median and IQR, the whiskers indicate minimum and maximum values, and the white circles indicate the mean.



# Multimedia Appendix 1

Originally published Figure 2.

[PNG File, 95 KB-Multimedia Appendix 1]



This is a non-peer-reviewed article. Submitted 15.03.22; accepted 15.03.22; published 17.03.22.

Please cite as:

Limmroth V, Bayer-Gersmann K, Mueller C, Schürks M

Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon  $\beta$ -1b: Observational Study

JMIR Form Res 2022;6(3):e38002

URL: https://formative.jmir.org/2022/3/e38002

doi: 10.2196/38002

PMID:

©Volker Limmroth, Kirsten Bayer-Gersmann, Christian Mueller, Markus Schürks. Originally published in JMIR Formative Research (https://formative.jmir.org), 17.03.2022. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on https://formative.jmir.org, as well as this copyright and license information must be included.

